On-Demand Webinar

Neoadjuvant CD40 Agonism Remodels the Tumor Immune Microenvironment in Locally Advanced Esophageal/Gastroesophageal Junction Cancer


Sotigalimab is an agonistic anti-CD40 mAb that can modulate antitumor immune responses. In a phase II clinical trial of sotigalimab combined with neoadjuvant chemoradiation (CRT) in locally advanced esophageal/gastroesophageal junction (E/GEJ) cancer with the primary outcome of efficacy as measured by pathologic complete response (pCR) rate, the combination induced pCR in 38% of treated patients. We investigated the mechanism of action of sotigalimab in samples obtained from this clinical trial. Tumor biopsies and peripheral blood samples were collected at baseline, following an initial dose of sotigalimab, and at the time of surgery after CRT completion from six patients. High dimensional single-cell techniques were used, including combined single-cell RNA-sequencing and proteomics (CITEseq) and multiplexed ion beam imaging, to analyze immune responses. Sotigalimab dramatically remodeled the immune compartment in the periphery and within the tumor microenvironment (TME), increasing expression of molecules related to antigen processing and presentation and altering metabolic pathways in myeloid cells. Concomitant with these changes in myeloid cells, sotigalimab treatment primed new T cell clonotypes and increased the density and activation of T cells with enhanced cytotoxic function. Sotigalimab treatment also induced a decrease in the frequency of Tregs in the TME. These findings indicate that a single dose of sotigalimab leads to enhanced antigen presentation that can activate T cells and induce new T cell clones. This restructuring of the TME provides elements which are critical to the development of effective antitumor immune responses and improved clinical outcomes.

MIBIsight: Gaining Insights from Your MIBI Data


Join us for a webinar where we delve into the transformative capabilities of MIBIsight, our cutting-edge bioinformatics data analysis and exploration software. MIBIsight is meticulously designed to unlock the full potential of spatial proteomic data acquired through our MIBIplus service, providing users with unparalleled insights into complex tissue microenvironments. In this session, we explore how MIBIsight empowers researchers to extract rich, nuanced information from their data with ease and precision. We will cover:

  • How to harness the power of MIBIsight software for deciphering complex spatial proteomic data
  • Discovering unique signatures and spatial relationships within tissue regions.
  • Our intuitive tool enables you to adjust cell classifications and generate comprehensive reports.
  • Exploration of complex spatial proteomic data through customized graphs and plots, optimizing research insights for publication and presentations.
Contact Us

<p style="text-align: center; margin-top: 2em;">Let us know how we can help you.</p>

    Immuno-oncology/CancerNeuroscienceInfectious DiseaseImmunologyStem CellOther


    Please contact me. I understand that I can choose to unsubscribe at any time by e-mailing marketing@ionpath.com.

    Contact Us

    We are using cookies on our website

    Please confirm, if you accept our tracking cookies. You can also decline the tracking and continue to visit our website without any data sent to third-party services.